D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof

Patent metadata

Field	Value
Publication number	US-10722489-B2
Application number	US-201916405569-A
Country	US
Kind code	B2
Filing date	May 7, 2019
Priority date	Oct 31, 2016
Publication date	Jul 28, 2020
Grant date	Jul 28, 2020

Abstract

This application discloses a D-3-phosphoglycerate dehydrogenase allosteric inhibitor and the use thereof. In one class is the benzoyl hydrazine compound for the allosteric site MDL-1 of the enzyme, and the other class is the furan compound for the allosteric site MDL-2 of the enzyme. In vitro enzymatic activity tests, cell viability tests and mouse xenograft model experiments confirm that the two classes of allosteric inhibitors can specifically inhibit the activity of D-3-phosphoglycerate dehydrogenase and delay the growth of cancer cells by reducing the overexpression of the enzyme in cancer cells. Same are used alone or in combination, or in combination with other anti-cancer drugs and can treat, prevent, or inhibit tumor diseases, including breast cancer, colon cancer, melanoma and non-small cell lung cancer.

First claim

What is claimed is:

1. A chemical compound having structural formula (II)

or a salt or a solvate thereof, wherein R 1 ′ and R 3 ′ are identical or different, wherein each of R 1 ′ and R 3 ′ independently represents hydrogen, hydroxyl, amino, carboxyl, alkyl, alkoxy, haloalkyl, carboxylic ester, sulfonamide, amide or N-alkyl substituted amide, wherein R 2 ′ is hydrogen, hydroxyl, amino, carboxyl, alkyl, alkoxy, haloalkyl, carboxylic ester, sulfonamide, amide or N-alkyl substituted amide, or wherein two adjacent substituents (R1′ and R2′ or R2′ and R3′) form part of a ring, wherein R 4 ′ is alkyl, haloalkyl, amino, cycloalkyl, substituted or unsubstituted aryl, wherein X is nitrogen or sulfur.

2. A chemical compound according to claim 1 , wherein when one or more of R 1 ′, R 2 ′ and R 3 ′ are one or more alkyl groups, the one or more alkyl groups are C1˜C12 alkyl groups, wherein when one or more of R 1 ′, R 2 ′ and R 3 ′ are one or more alkoxy groups, the one or more alkoxy groups are C1˜C8 alkoxy groups, wherein when one or more of R 1 ′, R 2 ′ and R 3 ′ are one or more haloalkyl groups, the one or more haloalkyl groups are C1˜C12 alkyl groups substituted by one or more halo, wherein when one or more of R 1 ′, R 2 ′ and R 3 ′ are one or more carboxylic ester groups, the one or more carboxylic ester groups are C1˜C8 ester group, wherein when one or more of R 1 ′, R 2 ′ and R 3 ′ are one or more N-alkyl substituted amide groups, the one or more N-alkyl substituted amide groups are C1˜C12 alkyl substituted amide group.

3. A chemical compound according to claim 1 , wherein when R 1 ′ and R 2 ′ or R 2 ′ and R 3 ′ are linked into ring, the two adjacent substituents represent buta-1,3-diene-1,4-diyl or buta-2-ene-1,4-dily.

4. A chemical compound according to claim 1 , wherein when R 4 ′ is an alkyl group, the alkyl group is a C1˜C12 alkyl group, wherein when R 4 ′ is a haloalkyl group, the haloalkyl group is a C1˜C12 alkyl group substituted by one or more halo, wherein when R 4 ′ is a cycloalkyl group, the cycloalkyl group is a C5˜C7 membered cycloalkyl group.

5. A chemical compound according to claim 1 , wherein when R 4 ′ is unsubstituted or substituted aryl, the aryl is phenyl, wherein the substituted aryl is 4-substituted phenyl.

6. A chemical compound according to claim 5 , wherein the substituent group on 4- of the 4-substituted phenyl is C1˜C6 alkyl, C1˜C6 alkyl group substituted by one or more halo, nitro, or C1˜C4 alkoxy.

7. A chemical compound according to claim 1 , wherein the compound having structural Formula (II) is one of the following compounds (PKUMDL-WL-2201 to PKUMDL-WL-2231):

8. A pharmaceutical composition for preparing PHGDH inhibitors comprising a compound having structural Formula (II) according to claim 1 , or a pharmaceutical salt thereof.

Assignees

• Univ Beijing

Inventors

• Lai Luhua
• Liu Ying
• Wang Qian
• Liu Pei

Classifications

• A61K31/341 Primary

  not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine · CPC title

• A61K31/15 Primary

  Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)} · CPC title

• A61P35/00

  Antineoplastic agents · CPC title